• Meghan E Ramsey, Anthony J Faugno, Wendy B Puryear, Brian C Lee, Alexa D Foss, Lester H Lambert, Frances E Nargi, Gregory P Bopp, Lauren P Lee, Christina M Rudzinski, Benjamin L Ervin, Jonathan A Runstadler, and Nicholas S Hill.
• Biotechnology and Human Systems Division, Massachusetts Institute of Technology, Lincoln Laboratory, Lexington, Massachusetts.
• Respir Care. 2023 Jan 1; 68 (1): 8178-17.

BackgroundIn the midst of the COVID-19 pandemic, noninvasive respiratory support (NRS) therapies such as high-flow nasal cannula (HFNC) and noninvasive ventilation (NIV) were central to respiratory care. The extent to which these treatments increase the generation and dispersion of infectious respiratory aerosols is not fully understood. The objective of this study was to characterize SARS-CoV-2 aerosol dispersion from subjects with COVID-19 undergoing NRS therapy.MethodsSeveral different aerosol sampling devices were used to collect air samples in the vicinity of 31 subjects with COVID-19, most of whom were receiving NRS therapy, primarily HFNC. Aerosols were collected onto filters and analyzed for the presence of SARS-CoV-2 RNA. Additional measurements were collected in an aerosol chamber with healthy adult subjects using respiratory therapy devices under controlled and reproducible conditions.ResultsFifty aerosol samples were collected from subjects receiving HFNC or NIV therapy, whereas 6 samples were collected from subjects not receiving NRS. Only 4 of the 56 aerosol samples were positive for SARS-CoV-2 RNA, and all positive samples were collected using a high air flow scavenger mask collection device placed in close proximity to the subject. The chamber measurements with healthy subjects did not show any significant increase in aerosol dispersion caused by the respiratory therapy devices compared to baseline.ConclusionsOur findings demonstrate very limited detection of SARS-CoV-2-containing aerosols in the vicinity of subjects with COVID-19 receiving NRS therapies in the clinical setting. These results, combined with controlled chamber measurements showing that HFNC and NIV device usage was not associated with increased aerosol dispersion, suggest that NRS therapies do not result in increased dispersal of aerosols in the clinical setting.Copyright © 2023 by Daedalus Enterprises.

18 keywords...

hide…